Hereditary‐like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin‐based chemotherapy after radical nephroureterectomy than do sporadic tumours. (13th August 2013)

• Record Type: Journal Article
• Authors: Hollande, Clémence; Colin, Pierre; de, Thibault; Audenet, François; Yates, David R.; Phé, Véronique; Ouzzane, Adil; Droupy, Stéphane; Ruffion, Alain; de, Alexandre; Guy, Laurent; Cussenot, Olivier; Rozet, François; Xylinas, Evanguelos; Zerbib, Marc; Spano, Jean‐Philippe; Khayat, David; Bitker, Marc‐Olivier; Rouprêt, Morgan
• Is Part Of: BJU international. Volume 113:Number 4(2014:Apr.)
• Page Start: 574
• Page End: 580
• Publication Date: 2013-08-13
• Subjects: Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12308
• Languages: English
• ISSNs: 1464-4096

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bju12308-sec-0001" sec-type="section"> <title>Objective</title> <p> <list id="bju12308-list-0001" list-type="bullet"> <list-item> <p>To evaluate the impact of 'hereditary‐like' status in upper tract urothelial carcinoma (UTUC) on the survival of patients who have undergone radical nephroureterectomy (RNU) and adjuvant chemotherapy.</p> </list-item> </list> </p> </sec> <sec id="bju12308-sec-0002" sec-type="section"> <title>Patients and Methods</title> <p> <list id="bju12308-list-0002" list-type="bullet"> <list-item> <p>A multicentre retrospective study was performed on all patients with high‐risk UTUC who underwent RNU and adjuvant cisplatin‐based chemotherapy.</p> </list-item> <list-item> <p>Using a patient risk identification tool, we distinguished tumours suspected to be hereditary from sporadic tumours and compared survival rates.</p> </list-item> </list> </p> </sec> <sec id="bju12308-sec-0003" sec-type="section"> <title>Results</title> <p> <list id="bju12308-list-0003" list-type="bullet"> <list-item> <p>A total of 112 patients with a median age of 67 years were included. Hereditary‐like tumour status was detected in 35 patients (31.3%), while 77 patients (68.7%) had sporadic tumours.</p> </list-item> <list-item> <p>The median age was significantly younger in the hereditary‐like tumour group (56.0 vs 69.8 years, <italic>P</italic> < 0.001). Overall survival (OS) after chemotherapy was significantly better in the group with hereditary‐like tumours than in the group with sporadic tumours (5‐year OS: 48.2 vs 32%; <italic>P</italic> = 0.008).</p> </list-item> <list-item> <p>The cancer‐specific survival (CSS) rate was significantly better in the group with 'hereditary‐like' tumours than in the group with sporadic tumours (5‐year CSS: 58 vs 35%; <italic>P</italic> = 0.006).</p> </list-item> <list-item> <p>Although there was a trend in favour of the hereditary‐like tumours, we observed no significant difference regarding progression‐free survival (PFS) between the two groups (5‐year PFS: 71 vs 52%; <italic>P</italic> = 0.07).</p> </list-item> </list> </p> </sec> <sec id="bju12308-sec-0004" sec-type="section"> <title>Conclusion</title> <p> <list id="bju12308-list-0004" list-type="bullet"> <list-item> <p>Adjuvant chemotherapy after RNU improves survival outcomes in patients with hereditary‐like UTUC compared with those with sporadic tumours.</p> </list-item> </list> </p> </sec> </abstract>